Lipocine Inc. Files 8-K for Material Agreements
Ticker: LPCN · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $30.24, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
TL;DR
Lipocine Inc. filed an 8-K on Oct 22, 2024, detailing material agreements and changes to security holder rights.
AI Summary
On October 22, 2024, Lipocine Inc. entered into a material definitive agreement. The company also made modifications to the rights of its security holders and amended its articles of incorporation or bylaws. This filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Lipocine Inc., including new agreements and potential changes affecting shareholder rights, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce new risks or alter existing ones for investors.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- October 22, 2024 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (address) — Principal Executive Offices
- Salt Lake City, Utah 84108 (address) — Principal Executive Offices
FAQ
What specific material definitive agreement did Lipocine Inc. enter into on October 22, 2024?
The filing indicates the entry into a material definitive agreement but does not specify its nature or terms within the provided text.
What are the key modifications to the rights of security holders mentioned in the filing?
The filing states that there were material modifications to the rights of security holders, but the specific details of these modifications are not provided in the excerpt.
What amendments were made to Lipocine Inc.'s articles of incorporation or bylaws?
The filing notes amendments to the articles of incorporation or bylaws, but the specific changes are not detailed in the provided text.
What is the Commission File Number for Lipocine Inc.'s 8-K filing?
The Commission File Number for Lipocine Inc. is 001-36357.
When is Lipocine Inc.'s fiscal year end?
Lipocine Inc.'s fiscal year ends on December 31.
Filing Stats: 1,372 words · 5 min read · ~5 pages · Grade level 13.3 · Accepted 2024-10-22 18:38:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
- $30.24 — k (the "Preferred Stock") at a price of $30.24 per one-thousandth share (the "Purchase
- $0.001 — any is entitled to redeem the Rights at $0.001 per Right at any time prior to the time
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex3-1.htm (EX-3.1) — 15KB
- ex4-1.htm (EX-4.1) — 326KB
- form8-k_001.jpg (GRAPHIC) — 8KB
- 0001493152-24-042117.txt ( ) — 645KB
- lpcn-20241022.xsd (EX-101.SCH) — 3KB
- lpcn-20241022_lab.xml (EX-101.LAB) — 33KB
- lpcn-20241022_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: October 22, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer